RecoveryNot approvedEvidence tier: Human RCT

Hexarelin

Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA: Unapproved drugs

Evidence tier

Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 245 PubMed citations indexed.

Hexarelin in the literature

Potent synthetic GH secretagogue and ghrelin mimetic with additional cardioprotective effects via CD36 receptor activation; stimulates robust GH pulse with some cortisol spillover.

What the literature studies

GH Release & Cardioprotection

Evidence tier

Human RCT

Compounding record

Status not verified

Confidence
3/5

Regulatory record

Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source not verified; no checked date is assigned.

may desensitize GH receptors with prolonged use; cortisol and prolactin elevation observed.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.